NCT06632873 177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors
| NCT ID | NCT06632873 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Peking Union Medical College Hospital |
| Condition | SSTR2 and Integrin αVβ3 Positive Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2025-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 10 participants in total. It began in 2024-09-01 with a primary completion date of 2025-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Researchers has conducted extensive research on the treatment of neuroendocrine tumors with 177Lu-EB-TATE and the treatment of FAP-expressing tumors with 177Lu-EB-FAPI, and some researches have revealed 68Ga-TATE-RGD in imaging studies of neuroendocrine tumors to find that the dual-targeted tracer showed an increasing TBR, suggesting the tracer kinetic advantage of TATE-RGD; compared to the single-target tracer DOTATATE, the dual-target TATE-RGD probe has a clear advantage in detecting liver metastases of NETs, and it can be explored for potential therapeutic uses of TATE-RGD in future studies and used for related companion diagnostics in targeted radioisotope therapy (RLT).
Eligibility Criteria
Inclusion Criteria: * patients with clear pathological diagnosis and ineffective or progressing clinical conventional treatment; * tumor lesions with high SSTR2 and RGD untake confirmed on 68Ga-TATE-RGD PET/CT within one week before the injection of 177Lu-TATE-RGD; * signed written consent. Exclusion Criteria: * the exclusion criteria were a serum creatinine level of more than 150 μmol per liter, a hemoglobin level of less than 10.0 g/dl, a white-cell count of less than 4.0× 109/L, a platelet count of less than 100 × 109/L, a total bilirubin level of more than 3 times the upper limit of the normal range and a serum albumin level of more than 3.0 g per deciliter, cardiac insufficiency including carcinoid heart valve disease, a severe allergy or hypersensitivity to radiographic contrast material, claustrophobia; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06632873 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying SSTR2 and Integrin αVβ3 Positive Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06632873 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06632873 currently recruiting?
Yes, NCT06632873 is actively recruiting participants. Contact the research team at 13611093752@163.com for enrollment information.
Where is the NCT06632873 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06632873 clinical trial?
NCT06632873 is sponsored by Peking Union Medical College Hospital. The trial plans to enroll 10 participants.